Q1 EPS Estimates for USANA Health Sciences Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Stock analysts at Sidoti Csr cut their Q1 2025 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research report issued to clients and investors on Thursday, April 17th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.70 per share for the quarter, down from their previous forecast of $0.71. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.67 EPS, FY2025 earnings at $2.59 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.39 EPS.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $249.54 million during the quarter, compared to analysts' expectations of $243.08 million. During the same quarter in the previous year, the business posted $0.86 earnings per share.

A number of other equities research analysts also recently issued reports on USNA. Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Finally, StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.

USANA Health Sciences Trading Up 5.2 %

Shares of NYSE:USNA traded up $1.25 on Friday, reaching $25.49. 105,156 shares of the company's stock were exchanged, compared to its average volume of 119,529. USANA Health Sciences has a twelve month low of $23.10 and a twelve month high of $49.78. The company has a fifty day moving average of $28.16 and a 200-day moving average of $33.38. The company has a market capitalization of $481.89 million, a price-to-earnings ratio of 9.01, a PEG ratio of 0.93 and a beta of 1.00.

Insider Activity at USANA Health Sciences

In other news, insider Joshua Foukas sold 5,732 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jim Brown sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company's stock, valued at $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock valued at $500,285 over the last three months. 0.63% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $28,000. Versant Capital Management Inc boosted its holdings in USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after acquiring an additional 971 shares during the last quarter. Parallel Advisors LLC increased its position in USANA Health Sciences by 8,141.2% during the 1st quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock valued at $38,000 after purchasing an additional 1,384 shares during the period. KLP Kapitalforvaltning AS bought a new position in USANA Health Sciences during the 4th quarter worth approximately $83,000. Finally, Quantbot Technologies LP acquired a new position in shares of USANA Health Sciences in the 4th quarter worth approximately $132,000. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.